Overexpression and amplification of the new (c-erbB2, ERBB2) protooncogene have been implicated in the development of aggressive human breast cancer. To directly assess the effect of mammary gland-specific expression of the neu protooncogene, transgenic mice carrying unactivated neu under the transcriptional control of the mouse mammary tumor virus promoter/enhancer were established. By contrast to the rapid tumor progression observed in several transgenic stra carrying the activated neu transgene, expression of unactivated neu in the mammary epithelium resulted in the development of focal mammary tumors after long latency. The majority of the mammar tumors analyzed expressed elevated levels of neu-encoded mINA anid protein. Overexpresslon of neu in the mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity and the de novo tyrosine phosphorylation of several cellular proteins. Interestingly, many of the tumor-baring transgenic mice developed secondary metastatic tumors in the lung. These observations suggest that overexpression of the unactivated neu protein can induce metastatic disease after long latency.
The neu protooncogene encodes a 185-kDa transmembrane protein that is a member of the epidermal growth factor receptor family (1) (2) (3) (4) . Oncogenic activation of neu can occur through a point mutation in the transmembrane domain (5) , deletion of the extracellular domain (6) , or overexpression (7) (8) (9) . Amplification and overexpression of the human homologue of neu (c-erbB2; human gene symbol, ERBB2) have been observed in a large percentage ofprimary breast cancers (1, [10] [11] [12] [13] and appear to be inversely correlated with the survival of the patient (11, 13) .
Given the close correlation between neu overexpression and mammary carcinogenesis, a number of laboratories have been interested in directly testing the tumorigenic potential of the neu oncogene in the mammary epithelium of transgenic mice. Initially, this was accomplished by generating several lines of transgenic mice carrying the activated rat neu oncogene under the transcriptional control ofthe mouse mammary tumor virus (MMTV) promoter/enhancer (14) (15) (16) . In several strains of MMTV/activated neu mice, early onset of transgene expression in the mammary epithelium of female mice was associated with the synchronous development of tumors involving the entire mammary epithelium. These results suggested that expression of activated neu requires few, if any, additional genetic events to transform the mammary epithelial cell (14) .
These studies suggested that activated neu can act as a potent oncogene in the mammary epithelium. However, overexpression of the unactivated neu protein may be the primary mechanism contributing to human breast cancer, since examination of primary breast cancer biopsy samples has thus far failed to reveal comparable activating mutations (13, 17) . To directly test the oncogenic potential of the unactivated neu protein in the mammary epithelium, six lines of transgenic mice carrying a MMTV/unactivated neu fusion gene were derived. Overexpression of the unactivated neu product in the female mammary epithelium of five of these lines resulted in appearance of focal mammary tumors that metastasized with high frequency. These observations support the hypothesis that elevated expression of neuassociated tyrosine kinase activity in the mammary epithelium induces metastatic disease.
MATERIALS AND METHODS DNA Constructions and Generation ofTransgenic Mice. The recombinant plasmid pMMTVneuN was established by inserting the HindIII-EcoRI fragment encoding the unactivated neu cDNA and simian virus 40 (SV40) polyadenylylation and splicing signals from pSV2neuN (5) into the corresponding HindIII-EcoRI sites ofthe plasmid pMMTVneuNT (14) . The plasmid pASV, which contains SV40 early splice and polyadenylylation signals, was constructed as described (14) . The /3-casein riboprotection probe was obtained from J. Rosen (Baylor College of Medicine) and was cloned as a 205-base-pair Pst I fragment in the plasmid pSP64 (Promega). The internal control plasmid rpL3227.3.7 was obtained from M. Shen (Harvard Medical School) and encodes the Xho II-Dra I fragment of the mouse ribosomal protein gene rpL32 inserted into the corresponding sites of the plasmid pBluescript KS (Stratagene). All plasmid DNAs were isolated and purified as described by Sinn et al. (18) . To derive transgenic mice carrying the MMTV/unactivated neu transcription unit, the pMMTVneuN Sph I-EcoRI fragment was microinjected into the pronuclei of FVB/N fertilized one-cell zygotes as described (18) . Transgenic progeny were identified by probing genomic DNA after Southern blot transfer (19) To assess the tissue specificity of transgene expression, 10 ,g of total RNA derived from 10 different tissues isolated from both male and female carriers of the various founder strains was subjected to RNase protection with a transgenespecific probe comprising the SV40 polyadenylylation/ splicing signals (pASV) (14) . Representative results from these RNase protection experiments for the MMTV/neu strains are summarized in Table 1 . Consistent with the observations made with other transgenic strains bearing MMTV/oncogenes, transgene expression was noted in mammary glands of female transgenic mice in five of six lines. Lower amounts of transgene transcript were detected in other tissues such as the salivary gland, spleen, thymus, and lung after longer exposure of the autoradiograms (Table 1) .
Although low-level expression of neu in the mammary epithelium did not initially affect mammary gland function or development, focal mammary tumors began to appear in these strains at 4 months of age. Histological examination of the tumors revealed focal mammary adenocarcinomas surrounded by hyperplastic mammary epithelium (Fig. 1B) . These tumors were composed of solid nests of pale intermediate cells that were morphologically identical to tumors associated with activated neu (25) . Transplantation of the tumor cells into the mammary fat pads of syngeneic recipients resulted in the appearance of tumors, confirming their neoplastic potential. In our best characterized line, N#202, 50% of female carriers developed mammary tumors by 205 days (Fig. 1A) . The appearance of tumors in this particular line was not strictly dependent on pregnancy, because virgin female transgenic mice also developed mammary tumors (data not shown). Furthermore, female transgenic mice derived from the other transgenic strains (N#169, N#510, N#721, and N#732) also developed tumors, albeit with later onset (Table 1) . However, male MMTV/neu carriers did not exhibit any phenotypic abnormalities.
Because overexpression of neu (ERBB2) in human breast cancer has been implicated as an important step in tumor progression, we compared the level of transgene expression in the tumors and in the adjacent mammary epithelium. To this end, 10 ,ug of total RNA derived from mammary tumors and adjacent mammary epithelium isolated from female N#202 transgenic mice was hybridized with a radiolabeled transgene-specific probe (pASV) and subjected to RNase digestion (Fig. 2) . To ensure that equal quantities of RNA were loaded, an rpL32 antisense probe was also included in the hybridization reactions. Representative results for several sets of matched tumor and adjacent mammary epithelium for the N#202 line are shown in Fig. 2 . Densitometric measurement of these autoradiograms revealed that many of the tumors (n = 16) expressed higher (10-to 50-fold) levels of transgene RNA than the adjacent mammary epithelium. However, several other matched sets of normal and tumor tissues (n = 7) expressed equivalent amounts of neu RNA (e.g., N#5741; Fig. 2 ). While there was some variation in transgene expression in the normal mammary epithelium, all mammary tumors examined expressed elevated levels of the neu transgene (Table 1) .
To establish whether the elevated expression of transgene transcripts observed in the tumor tissues resulted in a corresponding increase in neu protein levels, Western analyses with neu-specific antibodies were conducted on protein extracts of normal and neoplastic tissues. The level of neu Table 1 protein in the tumors was higher than in the adjacent epithelium (Fig. 3A) . Taken together, these observations suggest that elevated expression of neu may be an important step for tumorigenesis.
Mammary Gland-Specific Expression of neu Is Associated with the Induction of Metastatic Disease. Surprisingly, a high percentage of tumor-bearing MMTV/neu animals developed metastases to the lung (Fig. 1C) . Histological examination of lung tissue in these affected animals revealed the presence of multiple foci of metastatic mammary adenocarcinoma lodged in pulmonary vessels (Fig. 1C) . Like the primary mammary tumors, these metastatic lung tumors also expressed elevated levels of the neu transgene RNA (Fig. 2) . The (Table 1) . Consistent with these observations, metastatic foci could also be detected in lung tissue after transplantation of the primary tumors into the fat pads of normal syngeneic recipients.
To confirm that the tumors detected in the lung were of mammary origin, RNase protection analyses with a probe specific to the mammary differentiation marker, (3-casein, were performed on RNA derived from both primary and metastatic tumors (Fig. 2) (Fig. 3B) . By contrast, no comparable autophosphorylated species could be detected when extracts of nontransgenic control tissues or the adjacent mammary epithelium were assayed for kinase activity (Fig. 3B) . Because neu protein could readily be detected in the mammary epithelium adjacent to the tumor tissue (Fig. 3A) , these observations indicate that the neu-induced tumors possess higher neu-associated tyrosine kinase activity than the adjacent mammary epithelium.
DISCUSSION
Our observations provide direct evidence that expression of the protooncogenic form of neu results in a heritable development of metastatic mamI y tumors. In five independent strains of MMTV/unactivated neu mice (N#202, N#169, N#510, N#721, and N#732), expression of the transgene resulted in the appearance of focal mammary adenocarcinomas which eventually metastasized to the lung. Tumorigenesis in these lines was correlated with elevated expression of the neu transgene and an increase in neu-associated tyrosine kinase activity. These observations support the hypothesis that elevated expression of neu can induce the production of metastatic mammary adenocarcinomas.
Overexpression of neu has been frequently observed in human primary breast cancers (10) (11) (12) (13) and derived cell lines (1, 12, 27 (27) . Previous studies have demonstrated that transgenic mice expressing the activated neu oncogene in the mammary epithelium also develop mammary tumors which are cytologically indistinguishable from those associated with the neu protooncogene (14, 15) . However, malignant progression in strains carrying the MMTV/activated neu gene differs from the process observed here in the MMTV/unactivated neu transgenic mice. Mammary gland-specific expression of the activated neu oncogene in these strains was associated with the rapid and synchronous development of multifocal mammary tumors in both sexes (14) . These studies suggested that expression of activated neu was sufficient for mammary tumorigenesis. By contrast, expression of unactivated neu is not sufficient, since mammary epithelium adjacent to tumors expresses appreciable levels of neu protein (Fig. 3A) . It is conceivable that differences in the activity ofthe neu tyrosine kinase in transgenic mice expressing either the activated or the unactivated neu transgene account for this phenotypic variation. Consistent with this hypothesis is the observation that the neu-induced tumors possess higher tyrosine kinase activity than the adjacent mammary epithelium (Fig. 3B) (Fig. 3B ) the 185-kDa protein very likely represents the autophosphorylated form of neu.
The unexpected finding that many of the older tumorbearing neu transgenic animals developed pulmonary metastases may have important clinical implications. The observation that overexpression of neu in human breast cancer is associated with poor clinical outcome in node-negative women (28, 29) and the results of these transgenic experiments suggest that overexpression of neu can confer an enhanced metastatic potential upon the mammary tumor cell. Pulmonary metastases were also observed in transgenic strains carrying the MMTV/activated neu transgene (14) . However, metastasis in these mice was relatively infrequent. Because these activated neu tumors involve the entire mammary epithelium and thus considerably shorten the animals' survival, it is conceivable that the further steps necessary for metastatic progression do not have sufficient time to occur in these MMTV/activated neu mice. Consistent with this notion, metastasis in the MMTV/unactivated neu lines is observed only in mice that have carried mammary tumors for several months (Table 1 ). Determination ofthe mechanism by which the neu kinase is involved in the induction of metastatic disease awaits further analysis.
